Welcome to the 7th RAS-Targeted Drug Development Summit
As recent advances in next-generation modalities to target mutant RAS progress from the bench to the clinic, the 7th RAS-Targeted Drug Development Summit returns with a refreshed and comprehensive program featuring strategies to overcome resistance, leverage combination therapies and improve patient stratification strategies for optimizing RAS-targeted drug durability.
Join over 120 industry experts across 3 comprehensive days with deep-dive interactive sessions and data-driven presentations to accelerate RAS-targeting drugs to the patients in need.
Unmissable Agenda Highlights
Discover
Discover the latest modalities beyond covalent inhibitors paving the way for best-in-class, boasting improved durability of response, with talks on novel RAS-targeting degraders, molecular glues, cell therapies, vaccines and more with insights from Aethon Therapeutics, HB Therapeutics & Anocca
Deep-Dive
Deep dive into a variety of combination strategies for overcoming resistance, enhancing effectiveness, and prolonging treatment success for patients battling RAS-driven cancers with insights from Amgen, Bristol Myers Squibb & Verastem Oncology
Optimize
Optimize RAS-targeted drug efficacy by leveraging pan-(K)RAS inhibitors for deep and durable responses to treat PDAC, NSCLC and beyond with insights from Revolution Medicine, Pfizer & Abbisko Therapeutics
Divide & Conquer
Built with input from experts at Amgen, Verastem Oncology, Bristol Myers Squibb, and many others, the program has been specifically designed to address the key challenges at each stage of development. The summit will shine of spotlight on the RAS fields latest innovations and advancements.
A snapshot of key sessions featured in each track across the 2025 program:
Track A: Drug Discovery & Preclinical Development
AZD0022: a Potent, Oral KRASG12D-Selective inhibitor that Drives Robust Anti-Tumor Activity in KRASG12D Models
- Michael Niedbala, Executive Director, Early Oncology Projects, AstraZeneca
Spearheading the Development of TCR-Based Approaches for Inhibition of RAS-Driven Cancers in Resistant Patient Populations
- Reagan Jarvis, Chief Executive Officer,
Anocca
Leveraging Strategies for Selective Targeting of NRAS & Q61 Mutations for Cancer Treatment
- Shohei Koide, Professor, New York University Grossman School of Medicine
Track B: Translation & Clinical Development
Pan-Raf-MEK Non-Degrading Molecular Glue NST-628: Pre-Clinical Modelling & Incorporation of PD, ctDNA & Circulating Tumor Markers in Guiding Dose Escalation & Patient Selection in the FIH Clinical Study
- Philip Komarnitsky, Chief Medical Officer, Nested Therapeutics
VS-7375: An Oral, Selective KRAS G12D (ON/OFF) Inhibitor with Potent Preclinical Anti-Tumor Efficacy & Promising Initial Clinical Data
- Jonathan Pachter, Chief Scientific Officer, Verastem Oncology
Phase I/II Study of D3S-001, a New Generation KRAS G12C Inhibitor in Advanced/Metastatic Solid Tumors with KRAS G12C Mutations
- Cheng Chen, Senior Medical Director, Clinical Lead for KRAS G12C Program, D3 Bio
Explore the Full Event Guide
- The Only Industry Dedicated RAS Forum
- 40+ World Class Speakers
- 3 Exclusive Days of Data Driven Content
- 2 Deep Dive Workshop Sessions
- 1 Combination Strategies Focus Day
Attending Companies Include
Explore the Agenda
Hear the latest industry breakthroughs, cutting edge strategies as well as overcome RAS drug bottlenecks during our packed agenda consisting of deep dive workshops, interactive roundtables and data-driven case studies.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of RAS biopharma deals.
Join RAS Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.